PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report ...

The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Each Baqsimi device includes 1 dose of glucagon and cannot be refused ... the dose does not need to be inhaled. If there is no response after 15 minutes, an additional 3mg dose from a new device ...

Gvoke, Xeris’s ready-to-use glucagon therapy ... The company’s key candidate, seralutinib, is inhaled and targets pathways involved in abnormal cellular growth problems, inflammation, and ...

Gvoke VialDx is expected to be available in the third quarter of 2025. The Food and Drug Administration (FDA) has approved Gvoke VialDx ™ (glucagon) for intravenous use as a diagnostic aid ...

Diabetic neuropathy refers to nerve damage that develops gradually and is caused by long-term high blood sugar levels. While there’s no cure, managing blood sugar levels can slow its progression ...

Because the primary function of AAT is to protect lungs from inflammation caused by infection and inhaled irritants, low levels of circulating AAT can result in lung-related symptoms, including ...